Ravgen and Myriad in patent dispute over DNA testing tech
24-12-2020
Illumina to acquire Jeff Bezos-backed cancer testing company
23-09-2020
Michael Vi / Shutterstock.com
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Illumina, Roche, genetic testing, patent infringement, DNA, non-invasive, US District Court for the District of Delaware, diagnostic, innovation, Ravgen
